Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis
These results show that FC and CRP analyses may contribute to a noninvasive monitoring strategy in clinical practice.ClinicalTrials.gov numbers: NCT03518086, NCT03524092.
Authors
- Remo Panaccione (ORCID: https://orcid.org/0000-0002-5247-940X)
- Richard Moses (ORCID: https://orcid.org/0000-0002-1423-089X)
- Simin Baygani
- Parambir S. Dulai (ORCID: https://orcid.org/0000-0002-9514-2321)
- Britta Siegmund (ORCID: https://orcid.org/0000-0002-0055-958X)
- Deborah A. Fisher (ORCID: https://orcid.org/0000-0002-8886-3382)
- Taku Kobayashi (ORCID: https://orcid.org/0000-0002-2073-4234)
- Simon P.L. Travis (ORCID: https://orcid.org/0000-0002-2690-4361)
- Faye Chan-Diehl
- Alissa J. Walsh (ORCID: https://orcid.org/0000-0002-8994-1186)
Institutions
- Northwestern University (US)
- Eli Lilly (United States) (US)
- University of Calgary (CA)
- John Radcliffe Hospital (GB)
- Humboldt-Universität zu Berlin (DE)
- University of Oxford (GB)
- Oxford Biomedical Research (US)
- Kitasato Institute Hospital (JP)
- Kitasato University (JP)
- Freie Universität Berlin (DE)
Publication Details
- Journal
- Crohn s & Colitis 360
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1093/crocol/otaf043
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Eli Lilly and Company